Citation Report

List of articles citing

Effect of tadalafil on chronic pelvic pain and prostatic inflammation in a rat model of experimental autoimmune prostatitis

DOI: 10.1002/pros.23514
Prostate, 2018, 78, 707-713.

#	Paper	IF	Citations
23	Once-daily 5 mg tadalafil oral treatment for patients with chronic prostatitis/chronic pelvic pain syndrome. *Therapeutic Advances in Urology*, **2018**, 10, 377-381	3.2	8
22	Chronic pelvic pain and prostate inflammation in rat experimental autoimmune prostatitis: Effect of a single treatment with phosphodiesterase 5 inhibitors on chronic pelvic pain. *Prostate*, **2018**, 78, 1157-1165	4.2	11
21	Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms: What Is the Role and Significance of Inflammation?. *Current Urology Reports*, **2019**, 20, 54	2.9	19
20	A phosphodiesterase 5 inhibitor, tadalafil, suppresses stromal predominance and inflammation in a rat model of nonbacterial prostatitis. *BMC Urology*, **2019**, 19, 99	2.2	8
19	The effect of using tadalafil 5 mg/day on neutrophil-lymphocyte and platelet-lymphocyte ratios in mild-medium and severe erectile dysfunction patients; and comparison of clinical response. *Andrologia*, **2019**, 51, e13347	2.4	4
18	Effect of alcohol on chronic pelvic pain and prostatic inflammation in a mouse model of experimental autoimmune prostatitis. *Prostate*, **2019**, 79, 1439-1449	4.2	21
17	Interventions to chronic prostatitis/Chronic pelvic pain syndrome treatment. Where are we standing and what's next?. *European Journal of Pharmacology*, **2019**, 857, 172429	5.3	5
16	Voiding behavior and chronic pelvic pain in two types of rat nonbacterial prostatitis models: Attenuation of chronic pelvic pain by repeated administration of tadalafil. *Prostate*, **2019**, 79, 446-453	4.2	6
15	Comparison of cernitin pollen extract vs tadalafil therapy for refractory chronic prostatitis/chronic pelvic pain syndrome: A randomized, prospective study. *Neurourology and Urodynamics*, **2020**, 39, 1994-2002	2.3	0
14	Effect of Eriocalyxin B on prostatic inflammation and pelvic pain in a mouse model of experimental autoimmune prostatitis. *Prostate*, **2020**, 80, 1394-1404	4.2	2
13	Aliskiren, tadalafil, and cinnamaldehyde alleviate joint destruction biomarkers; MMP-3 and RANKL; in complete Freund's adjuvant arthritis model: Downregulation of IL-6/JAK2/STAT3 signaling pathway. *Saudi Pharmaceutical Journal*, **2020**, 28, 1101-1111	4.4	4
12	Phosphodiesterase type 5 inhibitor therapy provides sustained relief of symptoms among patients with chronic pelvic pain syndrome. *Translational Andrology and Urology*, **2020**, 9, 391-397	2.3	4
11	Inflammation is a target of medical treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia. *World Journal of Urology*, **2020**, 38, 2771-2779	4	16
10	The PDE5 inhibitor udenafil ameliorates nonalcoholic fatty liver disease by improving mitochondrial function. *Biochemical and Biophysical Research Communications*, **2021**, 558, 57-63	3.4	2
9	IL-6/STAT3 pathway is involved in the regulation of autophagy in chronic non-bacterial prostatitis cells, and may be affected by the NLRP3 inflammasome. *Ultrastructural Pathology*, **2021**, 45, 297-306	1.3	0
8	Melatonin attenuates prostatic inflammation and pelvic pain via Sirt1-dependent inhibition of the NLRP3 inflammasome in an EAP mouse model. *Prostate*, **2021**, 81, 1179-1190	4.2	1
7	[Experimental rodent models of chronic prostatitis: effect of phosphodiesterase 5 inhibitor on chronic pelvic-pain-related behavior]. *Folia Pharmacologica Japonica*, **2019**, 154, 259-264	0	

6	Tissue Kallikrein Protects Rat Prostate against the Inflammatory Damage in a Chronic Autoimmune Prostatitis Model via Restoring Endothelial Function in a Bradykinin Receptor B2-Dependent Way.. *Oxidative Medicine and Cellular Longevity*, **2022**, 2022, 1247806	6.7	
5	The role of prostate inflammation in the pathogenesis of urethral strictures occurring after transurethral resections.. *Revista Internacional De Andrologí*, **2022**,	0.6	
4	HA/CD44 Regulates the T Helper 1 Cells Differentiation by Activating Annexin A1/Akt/mTOR Signaling to Drive the Pathogenesis of EAP. *Frontiers in Immunology*, **2022**, 13,	8.4	0
3	Treatment with the soluble guanylate cyclase activator BAY 60‐2770 normalizes bladder function in an in vivo rat model of chronic prostatitis. *European Journal of Pharmacology*, **2022**, 927, 175052	5.3	0
2	Comment on "Tadalafil monotherapy in management of chronic prostatitis/chronic pelvic pain syndrome: a randomized double-blind placebo controlled clinical trial"		
1	Association between the presence of bacteria in prostate tissue and histopathology in biopsies from men not complaining of lower urinary tract symptoms. **2022**,		0